CERRI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.177
EU - Europa 12.434
AS - Asia 9.106
SA - Sud America 1.308
AF - Africa 189
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 14
Totale 41.256
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.822
IT - Italia 6.119
SG - Singapore 2.986
GB - Regno Unito 2.381
CN - Cina 2.149
HK - Hong Kong 1.015
BR - Brasile 989
VN - Vietnam 969
SE - Svezia 773
DE - Germania 687
FR - Francia 506
BD - Bangladesh 489
FI - Finlandia 380
RU - Federazione Russa 371
UA - Ucraina 306
KR - Corea 250
TR - Turchia 245
NL - Olanda 238
IN - India 228
ID - Indonesia 191
CA - Canada 171
JP - Giappone 133
BG - Bulgaria 130
MX - Messico 127
AR - Argentina 103
IE - Irlanda 92
IQ - Iraq 75
PL - Polonia 64
ES - Italia 62
PK - Pakistan 61
ZA - Sudafrica 56
EC - Ecuador 49
BE - Belgio 47
CO - Colombia 39
AT - Austria 35
RO - Romania 34
VE - Venezuela 34
AE - Emirati Arabi Uniti 33
LT - Lituania 32
CL - Cile 31
MA - Marocco 28
CH - Svizzera 27
MY - Malesia 26
SA - Arabia Saudita 26
TW - Taiwan 24
EG - Egitto 23
JO - Giordania 23
PE - Perù 22
TN - Tunisia 20
AU - Australia 19
DZ - Algeria 18
IR - Iran 18
PY - Paraguay 18
UZ - Uzbekistan 18
CZ - Repubblica Ceca 17
KE - Kenya 17
AZ - Azerbaigian 16
TH - Thailandia 16
NP - Nepal 15
PH - Filippine 14
UY - Uruguay 14
AL - Albania 13
LV - Lettonia 13
DK - Danimarca 12
DO - Repubblica Dominicana 12
HR - Croazia 11
IL - Israele 11
HU - Ungheria 10
RS - Serbia 10
NZ - Nuova Zelanda 9
EU - Europa 8
GE - Georgia 8
JM - Giamaica 8
SN - Senegal 8
BO - Bolivia 7
CR - Costa Rica 7
EE - Estonia 7
KG - Kirghizistan 7
NO - Norvegia 7
SI - Slovenia 7
SY - Repubblica araba siriana 7
GR - Grecia 6
KZ - Kazakistan 6
OM - Oman 6
PT - Portogallo 6
BH - Bahrain 5
BY - Bielorussia 5
ET - Etiopia 5
LB - Libano 5
NI - Nicaragua 5
PS - Palestinian Territory 5
CY - Cipro 4
HN - Honduras 4
KH - Cambogia 4
KW - Kuwait 4
LU - Lussemburgo 4
MD - Moldavia 4
MK - Macedonia 4
QA - Qatar 4
TT - Trinidad e Tobago 4
Totale 41.193
Salva come PNG Salva come JPEG
Città #
Singapore 2.013
Ashburn 1.947
Santa Clara 1.734
Fairfield 1.687
Southend 1.635
Hong Kong 988
Woodbridge 988
Chandler 947
San Jose 828
Houston 752
Seattle 618
Wilmington 546
Cambridge 515
Hefei 514
Beijing 481
Dearborn 469
Milan 469
Council Bluffs 467
Ann Arbor 444
Nyköping 444
Jacksonville 426
Rome 385
London 367
New York 338
Ho Chi Minh City 268
Helsinki 261
The Dalles 259
Los Angeles 255
Hanoi 244
Modena 240
Seoul 206
San Diego 179
Chicago 173
Jakarta 145
Naples 141
Bologna 132
Dallas 132
Sofia 124
Princeton 123
Lauterbourg 117
Florence 113
Eugene 105
Buffalo 103
Tokyo 103
Palermo 100
Shanghai 97
Munich 94
Izmir 93
Moscow 93
São Paulo 85
Redwood City 83
Orem 82
Bari 81
Salt Lake City 80
Phoenix 69
Dublin 67
Catania 66
Frankfurt am Main 65
Turin 62
Boardman 61
Bremen 56
Columbus 56
Reggio Emilia 53
Montreal 52
Mexico City 49
Da Nang 46
Atlanta 45
Toronto 45
Verona 44
Genoa 42
San Francisco 42
Brooklyn 40
Guangzhou 40
Warsaw 39
Brussels 38
Chennai 38
Dong Ket 36
Elk Grove Village 35
Padova 35
Cagliari 34
Haiphong 34
Nuremberg 33
Parma 33
Denver 32
Poplar 32
Rio de Janeiro 32
Tampa 30
Turku 29
Baghdad 28
Manchester 28
Miano 28
Redondo Beach 28
Lahore 27
Mumbai 27
Ankara 26
Brescia 26
Falls Church 26
Mountain View 26
Norwalk 26
Boston 25
Totale 26.144
Salva come PNG Salva come JPEG
Nome #
INTERSTIZIOPATIA POLMONARE NON CLASSIFICABILE O SECONDARIA A CONNETTIVITE INDIFFERENZIATA. IMPORTANZA E DIFFICOLTÀ DI UNA DIAGNOSI DIFFERENZIALE. 3.851
Malattie infiltrative diffuse del polmone 1.207
Multidrug-resistant tuberculosis outbreak in an Italian prison: Tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays 802
Non-steroid agents for idiopathic pulmonary fibrosis 462
Acute exacerbation of Idiopathic Pulmonary Fibrosis: lessons learned from the Acute Respiratory Distress Syndrome 424
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 418
Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis 414
Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: The InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device) 404
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 403
Effectiveness of pulmonary rehabilitation in patients with INTERSTITIAL LUNG DISEASE of different etiology: a multicenter prospective study 375
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 361
Proteomics Analysis of Formalin-Fixed Paraffine-Embedded Tissue Reveals Key Proteins Related to Lung Dysfunction in Idiopathic Pulmonary Fibrosis. 360
Morbidity and Mortality in Patients with Idiopathic Pulmonary Fibrosis Undergoing Diagnostic Surgical Lung Biopsy 360
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 358
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. 355
Combination Therapy with Nintedanib and Sarilumab for the Management of Rheumatoid Arthritis Related Interstitial Lung Disease 348
NEW PERSPECTIVES IN DIAGNOSIS OF INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. VALIDATION STUDY OF AN ELECTRONIC STETHOSCOPE AND AD HOC SOFTWARE FOR DETECTION OF PULMONARY CRACKLES 347
Radiologic classification of usual interstitial pneumonia in rheumatoid arthritis-related interstitial lung disease: correlations with clinical, serological and demographic features of disease 344
INTERSTITIAL LUNG DISEASE RELATED TO RHEUMATOID ARTHRITIS. WHAT DO WE DON’T KNOW? THE LIRA STUDY (LUNG INVOLVEMENT IN RHEUMATOID ARTHRITIS) 337
Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review 329
Comparison of the tubercolin skin test and the ellispot blood test for the diagnosis of latent tuberculosis infection in pre-transplant dialysis patients 326
Ventilatory support and mechanical properties of the fibrotic lung acting as a “squishy ball” 325
Emerging drugs for idiopathic pulmonary fibrosis. 324
Use of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Case Study 323
Serial Ultrasound Assessment of Diaphragmatic Function and Clinical Outcome in Patients with Amyotrophic Lateral Sclerosis. 323
Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature 323
Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants 320
Expression of HOXB7 in the lung of patients with idiopathic pulmonary fibrosis: a proof of concept study. 316
Management of idiopathic pulmonary fibrosis. 314
Pulmonary stretch and lung mechanotransduction: Implications for progression in the fibrotic lung 311
Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis. 310
Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement 308
Molecular mechanisms and cellular contribution from lung fibrosis to lung cancer development. 308
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. 307
Rifabutin for treating pulmonary tuberculosis. 306
Lung fibrosis, bone marrow fibrosis and liver cirrhosis: A Short Telomere Syndrome or a casual association? 301
Best supportive care for idiopathic pulmonary fibrosis: Current gaps and future directions 301
Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline 301
Home Oxygen Saturation Monitoring And Quality Of Life Evaluation In Patients With Idiopathic Pulmonary Fibrosis: Preliminary Results From A Prospective Multicenter Trial 299
The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone 293
Clinical differences in sarcoidosis patients with and without lymphoma: a single-center retrospective cohort analysis. 293
A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM) 291
Pulmonary fibrosis and the many faces of UIP 291
Fibrotic idiopathic interstitial lung disease: the molecular and cellular key players. 291
Interstitial pneumonia with autoimmune features: A single center prospective follow-up study 289
Inspiratory effort and respiratory mechanics in spontaneously breathing patients with acute exacerbation of idiopathic pulmonary fibrosis: a retrospective matched control study. 289
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy 288
Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis 287
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis 285
Management of Idiopathic Pulmonary Fibrosis 285
HRCT Patterns Of Usual Interstitial Pneumonia In Rheumatoid Lung 285
AB1157 VALIDATION OF VECTOR (VELCRO CRACKLES DETECTOR) FOR THE DIAGNOSIS OF INTERSTITIAL LUNG DISEASE IN PATIENTS WITH CONNECTIVE TISSUE DISEASES 283
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report 282
Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature 281
Sarcoidosis: challenging diagnostic aspects of an old disease. 279
Quantiferon-TB Gold In-Tube Tests In Hospital Health Care Workers: A Five Years Experience 277
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis 276
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis 271
UNCLASSIFIABLE INTERSTITIAL LUNG DISEASE OR UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE? A CHALLENGING DIFFERENTIAL DIAGNOSIS 270
Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust 270
Ultrasound assessed Diaphragm Impairment is a Predictor of Outcomes in Acute Exacerbation of Chronic Obstructive Pulmonary Disease undergoing Non-Invasive Ventilation. 269
The encaged lung: rapidly progressive idiopathic pleurisy. 268
Real-life comparison of Pirfenidone and Nintedanib in patients with Idiopathic Pulmonary Fibrosis: a 24-month assessment. 265
Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay 263
A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis 263
Smoking-related interstitial lung disease 258
Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicenter retrospective study 258
Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review 255
Pulmonary Carcinosarcoma Arising in the Framework of an Idiopathic Pulmonary Fibrosis 251
The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease 250
INTERSTITIAL LUNG DISEASE IS ASSOCIATED TO INFECTIONS OF LOWER RESPIRATORY TRACT IN IMMUNOCOMPROMISED RHEUMATOID ARTHRITIS PATIENTS 248
Genetic commonality between inflammatory bowel disease and sarcoidosis: the beginning of the end or the end of the beginning? 247
RHEUMATOID ARTHRITIS RELATED INTERSTITIAL LUNG DISEASE. RADIOLOGICAL PATTERNS AND CORRELATIONS WITH CLINICAL, SEROLOGICAL AND DEMOGRAPHIC FEATURES OF DISEASE 247
The big clinical trials in idiopathic pulmonary fibrosis. 244
AB0472 PRIMARY SJOGREN SYNDROME ASSOCIATED INTERSTITIAL LUNG DISEASE: FEATURES, TREATMENT AND OUTCOME OF A MONOCENTRIC COHORT 243
Identification Of Potential Candidate Biomarkers In Lymphangioleiomyomatosis Using ITRAQ Proteomic Technology 242
Inappropriatezza prescrittiva dell'ossigenoterapia domiciliare a lungo termine 242
Repeated Quantiferon-TB Gold In-Tube Tests In Routine Clinical Practice: A Five Years Experience 241
Biological effects of COVID-19 on lung cancer: can we drive our decisions? 240
Empoyment of the ELISPOT blood test for the diagnosis of latent tuberculosis infection in dialysis patients awaiting renal transplantation 239
Validation of a Method for Automatic Detection of Lung Sounds in Fibrotic Interstitial Lung Disease 239
Etiology and Level of Lung Derangement Do Not Affect the Beneficial Effect of Pulmonary Rehabilitation in Patients with Interstitial Lung Diseases 237
Levels Of Fibulin-1 In The Lung And Serum Are Increased In Fibrotic Interstitial Lung Disease 235
Janus-faced amiodarone-induced pneumopathy 235
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 234
Challenges in idiopathic interstitial lung disease 232
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis 229
Interstitial lung disease is associated to infections of lower respiratory tract in immunocompromised rheumatoid arthritis patients 228
Copd, pulmonary fibrosis and ilas in aging smokers: The paradox of striking different responses to the major risk factors 228
Tubercolosi 224
Dissecting the role of mesenchymal stem cells in idiopathic pulmonary fibrosis: cause or solution? 221
Erratum: Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: A prospective study and review of the literature (Journal of Thoracic Disease (2019) 11 (1621-1628) DOI: 10.21037/jtd.2019.03.28) 219
Human mucosal associated invariant T cells detect bacterially infected cells 217
Impact of Mesenchymal Stromal/stem Cell Infusions on Circulating Inflammatory Biomarkers in COVID-19 Patients: Analysis of a Phase I-IIa Trial. 214
Differences between acute exacerbations of idiopathic pulmonary fibrosis and other interstitial lung diseases. 213
Unusual effectiveness of systemic steroids in Whipple disease. 209
Genetic testing in diffuse parenchymal lung disease 208
CHARACTERIZATION OF ANTI-MPO POSITIVE INTERSTITIAL LUNG DISEASE. CLINICAL-SEROLOGIC AND RADIOLOGIC FEATURES AND SURVIVAL 205
Physiological effects of lung protective ventilation in patients with lung fibrosis and usual interstitial pneumonia pattern versus primary ARDS: a matched-control study. 205
FRI0613 THERAPEUTIC STRATEGIES AND SURVIVAL IN PATIENTS WITH INTERSTITIAL PNEUMONIA WITH AUTOIMMUNE FEATURES 202
Totale 33.628
Salva come PNG Salva come JPEG
Categoria #
all - tutte 140.935
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 140.935
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021225 0 0 0 0 0 0 0 0 0 0 0 225
2021/20222.947 229 293 156 210 142 187 146 156 332 226 495 375
2022/20233.613 349 340 237 313 360 424 166 381 428 144 260 211
2023/20243.644 172 201 235 342 471 373 470 407 127 145 305 396
2024/20257.344 315 177 220 503 1.353 982 670 458 755 337 667 907
2025/202613.336 870 496 975 1.429 1.881 905 1.649 717 1.299 1.206 1.175 734
Totale 41.607